JP2022537289A5 - - Google Patents

Info

Publication number
JP2022537289A5
JP2022537289A5 JP2021574798A JP2021574798A JP2022537289A5 JP 2022537289 A5 JP2022537289 A5 JP 2022537289A5 JP 2021574798 A JP2021574798 A JP 2021574798A JP 2021574798 A JP2021574798 A JP 2021574798A JP 2022537289 A5 JP2022537289 A5 JP 2022537289A5
Authority
JP
Japan
Prior art keywords
amino acid
antibody
acid sequence
antibody molecule
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021574798A
Other languages
English (en)
Japanese (ja)
Other versions
JP7716342B2 (ja
JP2022537289A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/038143 external-priority patent/WO2020257289A2/en
Publication of JP2022537289A publication Critical patent/JP2022537289A/ja
Publication of JP2022537289A5 publication Critical patent/JP2022537289A5/ja
Application granted granted Critical
Publication of JP7716342B2 publication Critical patent/JP7716342B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021574798A 2019-06-17 2020-06-17 Cd138に対するヒト化抗体分子およびその使用 Active JP7716342B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962862457P 2019-06-17 2019-06-17
US62/862,457 2019-06-17
US202063035323P 2020-06-05 2020-06-05
US63/035,323 2020-06-05
PCT/US2020/038143 WO2020257289A2 (en) 2019-06-17 2020-06-17 Humanized antibody molecules to cd138 and uses thereof

Publications (3)

Publication Number Publication Date
JP2022537289A JP2022537289A (ja) 2022-08-25
JP2022537289A5 true JP2022537289A5 (enExample) 2023-06-26
JP7716342B2 JP7716342B2 (ja) 2025-07-31

Family

ID=71995040

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021574798A Active JP7716342B2 (ja) 2019-06-17 2020-06-17 Cd138に対するヒト化抗体分子およびその使用

Country Status (14)

Country Link
US (2) US12338291B2 (enExample)
EP (1) EP3983442A2 (enExample)
JP (1) JP7716342B2 (enExample)
KR (1) KR20220044939A (enExample)
CN (1) CN114269786B (enExample)
AU (1) AU2020294696A1 (enExample)
BR (1) BR112021025421A2 (enExample)
CA (1) CA3142021A1 (enExample)
IL (1) IL289034A (enExample)
MX (1) MX2021016098A (enExample)
MY (1) MY210065A (enExample)
PH (1) PH12021553109A1 (enExample)
TW (1) TW202112822A (enExample)
WO (1) WO2020257289A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY205689A (en) 2017-10-02 2024-11-06 Visterra Inc Antibody molecules to cd138 and uses thereof
CA3142021A1 (en) 2019-06-17 2020-12-24 Visterra, Inc. Humanized antibody molecules to cd138 and uses thereof
EP4363855A4 (en) * 2021-06-29 2025-04-16 Sheba Impact Ltd. DIAGNOSIS AND TREATMENT OF PANCREATIC CANCER
WO2023097254A1 (en) * 2021-11-24 2023-06-01 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
US20250064933A1 (en) * 2021-12-30 2025-02-27 St. Jude Children's Research Hospital, Inc. Chimeric antigen receptors comprising a pdz binding motif
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
EP0768377A1 (en) 1988-09-02 1997-04-16 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
AU662148B2 (en) 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
WO2001098539A2 (en) * 2000-06-21 2001-12-27 Hitachi Chemical Co., Ltd. Gene markers for lung cancer
US20060045877A1 (en) 2004-08-30 2006-03-02 Goldmakher Viktor S Immunoconjugates targeting syndecan-1 expressing cells and use thereof
EP3312196B1 (en) * 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
US20070054332A1 (en) 2005-08-10 2007-03-08 Alan Rapraeger Syndecan 1 ectodomain inhibits cancer
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2238169A1 (en) 2007-12-26 2010-10-13 Biotest AG Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
HRP20140604T1 (hr) 2007-12-26 2014-09-12 Biotest Ag Sredstva koja djeluju na cd138 i njihova upotreba
JP5817034B2 (ja) 2007-12-26 2015-11-18 バイオテスト・アクチエンゲゼルシヤフト Cd138を標的とする免疫複合体及びその使用
BRPI0821417A2 (pt) 2007-12-26 2015-06-16 Biotest Ag Método para diminuir a adesão de células de estroma a células tumorais que expressam cd138 em células tumorais de um indivíduo em necessidade do mesmo
BRPI1013990A2 (pt) 2009-05-06 2019-04-30 Biotest Ag método para tratar uma doença , e, combinação anticâncer
US9249467B2 (en) 2011-09-16 2016-02-02 Steven Goodison Bladder cancer detection composition, kit and associated methods
US10577543B2 (en) 2011-10-27 2020-03-03 Raymond Roger Wallage Efficient oil shale recovery method
SG11201402887SA (en) 2011-12-08 2014-07-30 Biotest Ag Uses of immunoconjugates targeting cd138
AU2013229786B2 (en) 2012-03-08 2017-06-22 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
GB201216002D0 (en) 2012-09-07 2012-10-24 Deutsches Rheuma Forschungszentrum Berlin Drfz Compositions adn methods
WO2014089354A1 (en) 2012-12-07 2014-06-12 The Regents Of The University Of California Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
CN103103197A (zh) 2013-01-30 2013-05-15 百奇生物科技(苏州)有限公司 抗cd138单克隆抗体可变区序列及其制备方法和应用
RU2611685C2 (ru) * 2015-07-20 2017-02-28 Илья Владимирович Духовлинов Гуманизированное моноклональное антитело, специфичное к синдекану-1
FI3494134T3 (fi) 2016-08-02 2026-02-19 Visterra Inc Muunneltuja polypeptidejä ja niiden käyttötapoja
EP3615573A4 (en) 2017-04-26 2021-01-20 Mitsubishi Tanabe Pharma Corporation SYNDECAN-1 (CD138) BINDING AGENTS AND THEIR USES
MY205689A (en) * 2017-10-02 2024-11-06 Visterra Inc Antibody molecules to cd138 and uses thereof
US12172986B2 (en) 2018-06-01 2024-12-24 Eisai R&D Management Co., Ltd Splicing modulator antibody-drug conjugates and methods of use
SG11202111330XA (en) 2019-06-07 2021-12-30 Adimab Llc Engineered ph-dependent anti-cd3 antibodies, and methods for their generation and use
CA3142021A1 (en) 2019-06-17 2020-12-24 Visterra, Inc. Humanized antibody molecules to cd138 and uses thereof
US12590171B2 (en) * 2019-09-27 2026-03-31 Nanjing GenScript Biotech Co., Ltd. Anti-VHH domain antibodies and use thereof
WO2023097254A1 (en) 2021-11-24 2023-06-01 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof

Similar Documents

Publication Publication Date Title
JP7575102B2 (ja) Muc18に特異的な抗体
JP7526099B2 (ja) 抗cd38抗体の皮下投薬
CN110799539B (zh) 抗4-1bb抗体及其制备和使用方法
US20250236669A1 (en) Antibodies That Bind Human Cannabinoid 1 (CB1) Receptor
JP2024174865A (ja) ヘテロ二量体四価特異性抗体およびこれらの使用
ES2674175T3 (es) Anticuerpos anti-CD38 conjugados
JP7791836B2 (ja) 抗cd3抗体及びその使用
JP7623939B2 (ja) 葉酸受容体アルファに特異的な抗体
TWI717678B (zh) Pd-l1抗體、其抗原結合片段及醫藥用途
JP7656330B2 (ja) Cd44に特異的な抗体
DK2831113T3 (en) ANTIBODIES AGAINST BRADYKININ-B1 RECEPTOR LIGANDS
CA3054824A1 (en) Anti-icos agonist antibodies and uses thereof
CN114401744B (zh) 用于治疗癌症的抗cd33抗体
JP7578289B2 (ja) Muc18に特異的な抗体
JP2021501566A5 (enExample)
IL295494A (en) Anti-human cd19 antibodies
WO2021173844A1 (en) C19 c38 bispecific antibodies
WO2023040940A1 (zh) Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症
JP2023537078A (ja) COVID-19を治療及び防止するためのSARS-CoV-2抗体
CA3146933A1 (en) Radiolabeled met binding proteins for immuno-pet imaging
TWI879267B (zh) 抗人類pd-l1抗體及其用途
CN118871465A (zh) 针对btla的抗体及其用途
TW202613175A (zh) Cdh3結合蛋白及其用途
JP2025532758A (ja) 癌の治療における使用のためのbtn3a活性化抗体、bcl2阻害剤及び低メチル化剤の併用
HK40128870A (zh) 抗人类pd-l1抗体及其用途